Home
About
Current Issue
Past Issues
Coming Issues
Editorial Board
Direct Links
Top
Abstract
Abbreviations and acronyms
MDD during IFN-α therapy
Prevention studies of IFN-MDD
Modifiable risk factors for IFN-MDD
Other populations at selective risk for MDD
Conclusion
References
Pharmacological aspects

Major depression during interferon-α treatment: vulnerability and prevention

Francis E. Lotrich, MD, PhD
Dialogues Clin Neurosci. 2009;11:417-425.
Abstract [EN] [ES] [FR]

Major Depressive Disorder (MDD) during interferons (IFN-α) treatment can occur within a few months of therapy, and shares many homologies with other forms of MDD, Most patients are resilient to the side effect ofinterferon-induced depression (IFN-MDD), but 15% to 40% are vulnerable. Several studies have employed antidepressants to prevent the incidence of an IFN-MDD episode, and the results suggest that prophylactic antidepressants may be specifically useful in those with pre-existing subthreshold depressive symptoms andlor a history of prior MDD episodes. Several other potential markers of vulnerability for IFN-MDD have been implicated in assessments of nondepressed patients before they start IFN-α These include poor sleep quality, premorbid elevations in inflammatory cytokines, genetic polymorphisms in the serotonin system, personality, and social support. The interplay of these factors strongly predicts who is at risk for IFN-MDD, and indicates several potentially modifiable targets for the personalized prevention of IFN-MDD,
Keywords: 
depression, cytokine, interferon, prevention, resilience, genetics 
Author Affiliations: 
Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania, USA (Francis E. Lotrich) 
Address for correspondence: 
lotrichfe@upmc.edu 
Abbreviations and acronyms: 
IFN-α
interferon-alpha
IL
interleukin
MDD
major depressive disorder
SSRI
selective serotinin reuptake inhibitor
 

Major Depressive Disorder (MDD) is common, costly, ​[1],​[2],​[3] and notably heterogeneous. Unfortunately, the accurate prediction and subsequent prevention of MDD episodes (MDEs) has been challenging. There is evidence that MDEs are variously associated with elevated psychosocial stress, the postpartum period, hypothyroidism, circadian changes, cerebrovascular disease, administration of inflammatory cytokines such as interferon-α (IFN-α), etc. Therefore, one approach for preventing a MDE could be to avoid stressful circumstances, pregnancy, cerebrovascular disease, and/or IFN-α therapy. However, this is often impractical. Thankfully, most people who are exposed to these various“triggers” do not develop MDD.

Identifying modifiable markers of risk in specificallyvulnerable people, and then mitigating these before MDD occurs, could be a better approach for preventing MDD. However, identifying causal risk factors that pre-exist in nondepressed people requires prospective studies, and the incidence of an MDE over 1 year is less than 2%. ​[4],​[5],​[6] The necessarily large epidemiologic studies have successfully identified predictive risk markers such as gender, age, cohort, family history, marital status, socioeconomic status, and stressful life events [6],[7] - but each of these is difficult or impossible to mitigate. Another strategy is needed for prospectively assessing nondepressed people for modifiable risk factors, and a related strategy is needed for examining whether specifically alleviating these vulnerabilities prevents MDE.

MDD during IFN-α therapy

One approach for delineating modifiable risk factors is to examine homogeneous groups of people who are definitively known to soon be exposed to a specific MDD-evoking situation. Towards this end, patients receiving IFN-α may be ideal candidates for examining MDD vulnerability. ​[8],​[9],​[10],​[11],​[12] MDD during IFN-α treatment (IFN-MDD) typically develops within the first 2 or 3 months of administration, ​[13],​[14],​[15],​[16],​[17] and occurs in about 15% to 40% of patients. [18] Thus, prospectively assessing IFN-MDD onset is feasible - and consequently it may be possible to determine predictive modifiable vulnerabilities in the 15% to 40% who subsequently develop IFN-MDD.

Of course, it is conceivable that IFN-MDD is unique, and that other forms of MDD are completely distinct from it. However, several lines of evidence indicate that IFN-MDD may successfully inform us about MDD in general. First, a variety of studies have found a robust relationship between IFN-α and MDE, including those demonstrating a dose-response relationship, [19],[20] studies with control groups, [16],​[19],​[20],​[21] and prospective documentations of worsening depression during IFN-a treatment with a return to baseline mood after discontinuation. ​[23],​[24],​[25] Thus, IFN-MDD is a replicable finding in prospective studies. Second, IFNMDD has phenomenological resemblance to MDD diagnosed in other situations. ​[21],​[22],​[23],​[24] That is, IFN-MDD is not simply fatigue and malaise but - similarly to MDD - involves anhedonia, depressed mood, irritability, anxiety, social withdrawal, poor concentration, altered sleep, personality- changes, and suicidal ideation (Table I). Third, MDD and IFN-MDD may share similar pathophysiologic mechanisms, as indicated by various independent lines of investigation:

Of further public health significance, the use of IFN-a is not rare. Almost 2% of the U.S. currently has chronic hepatitis C (HCV). [94] IFN-a is the only FDA-approved treatment for HCV, [95],[96] whereas about 170 million people worldwide have been infected with HCV. [97] Supporting IFN-α's widespread use, untreated chronic HCV can lead to cirrhosis, hepatocellular cancer, and liver failure, resulting in about 10 000 deaths per year in the US, [98] a rate which exceeds that from acquired immunodeficiency syndrome. [99] Unfortunately, IFN-MDD can potentially result in suicide, [38] dose reduction with risk for viral relapse, [16] discontinuation of treatment, [100],[101] and lower quality of life. [102],[103] Therefore, the two rationales for preventing IFN-MDD are that (i) this is a common and disabling syndrome; and (ii) it may be and ideal strategy for informing us about ways to prevent MDD in general.

Signs and symptoms MDD IFN-MDD
Anhedonia Yes Yes ​[24],​[25],​[26],​[27],​[28],​[29]
Depressed mood Yes Yes ​[26],​[27],​[28],​[29],​[30]
Sleep problems Yes Yes [26],[27],​[29],​[30],​[31],​[32]
Amotivation Yes Yes [27]
Decreased appetite Yes Yes [27],​[22],​[23],​[24],​[25],​[26],​[27],​[28],​[29],​[30]
Concentration changes Yes Yes ​[27],​[28],​[29],​[33],​[34],​[35],​[36]
Tearfulness Yes Yes [27]
Social withdrawal Yes Yes [27]
Guilt Yes Yes [26]
Interpersonal sensitivity Yes Yes [37]
Suicidal ideation Yes Yes [27],[29],[38]
Associated symptoms
Irritability Yes Yes [26],[27],[29],[30],[33]
Increased neuroticism Yes [40],[41] Not known
Care-seeking behaviors Yes [42] Seen in illness behavior [43]
Dependency/acting out
regression/somatization Yes [44],[45] Senn in illness behavior ​[45],​[46],​[47],​[48],​[49],​[50]
Table I. Comparison of Major Depressive Disorder (MDD) and interferon-a depressive disorder (IFN-MDD) during interferon-a treatment.

Prevention studies of IFN-MDD

A few prophylactic trials using selective serotonin reuptake inhibitors (SSRIs) have transpired. These prevention studies initiated SSRIs in patients who were not currently experiencing any MDE prior to beginning the IFN-a therapy (Table II) [80],[83],[85],​[80] . The first randomized placebo-controlled trial (RCT) was done in patients with metastatic melanoma, using very high doses of intravenous IFN-a. This initial study found strong evidence for prevention of IFN-MDD, with only 2/18 par oxe tinetreated patients (11%) developing IFN-MDD, as compared with 45% of the placebo-treated group. [80] Similarly, in three open-label trials of prophylactic SSRIs given to nondepressed HCV patients, only 3/32 patients (9%) developed IFN-MDD, despite all 32 patients having a prior history of affective disorder. These open-label studies are thus consistent with this RCT study, supporting the conclusion that preventative treatment with SSRIs may be useful.

However, two small RCT studies have now been completed in patients with HCV (Table II). Neither study found IFN-MDD prevention. [85],[106] Prophylactic SSRIs may therefore not be universally effective. Despite these two negative findings, one of these studies did report that 24/29 patients in the placebo group developed elevated depression symptoms compared with 10/23 in the paroxetine group. [106] Additionally, further exploratory analyses indicated that prevention may have been most successful for those subjects who already had high pretreatment baseline levels of depressive symptoms. [106] This would be an example of “indicated prevention” whereby treating “subthreshold” depression symptoms may prevent subsequent worsening to full categorical MDD. ​[108],​[109],​[110],​[111] It has been well-replicated that higher levels of pretreatment depression symptoms are associated with the development of IFN-MDD, [18],​[11],​[12],​[13],​[14],​[15],​[16],​[17],​[18],​[19],​[20],​[21] and these subthreshold symptoms may be an appropriate target for using preventive SSRIs. Another open possibility is that prophylactic SSRIs specifically prevented IFN-MDD in those with past histories of MDD in remission. This type of prevention would be consistent with the use of antidepressants to prevent recurrence of remitted MDD. ​[116],​[117],​[118],​[119]

To explore this latter possibility, we prospectively followed 31 patients who were not depressed at the onset of IFN-α therapy (as determined using a Structured Clinical Interview of DSM-IV Axis I diagnoses). All of these patients had no MDEs within 6 months prior to starting IFN-α, but they did have a history of past MDD. Ten of these patients were stably taking SSRIs. Only 20% (2/10) of the patients on SSRIs developed IFN-MDD, while 47.6% (10/21) not on antidepressants did. These results are numerically similar to the RCTs reviewed above. This very limited analysis suggests a more targeted use of SSRIs to prevent recurrence, limiting prophylactic SSRI to those patients who are known to have past MDD histories.

However, all of these studies have been very limited in size, and therefore power. Assessing all of the six published prevention studies and our open-label data combined - in a very exploratory type of meta-analysis - 15/97 (15%) patients receiving SSRIs prior to starting IFN-α developed IFN-MDD, compared with 36/99 (36%). This is a significant difference, χ2=8.2;P<0.001. However, limiting the meta-analysis to the three RCTs, 10/55 (18%) subjects randomized to pretreatment paroxetine developed IFN-MDD while 21/68 (31%) randomized to placebo did. The trend is numerically similar to the larger meta-analysis, but does not have the power to be significant in a chi-square test (χ2=1.98).

At this point, only tentative conclusions are possible: (i) Prophylactic SSRIs may plausibly cut in half the incidence of IFN-MDD. To conclusively determine this, however, will require a larger-size trial than those performed to date; (ii) SSRIs may specifically benefit subjects with either pre-existing depressive symptoms (ie, subthreshold depression) and/or a history of prior MDD. This is consistent either with studies of “indicated prevention” in which patients with subthreshold depression are prevented from worsening to full categorical MDD by about 30%, ​[108],​[109],​[110] or with studies preventing recurrence of MDD. ​[116],​[117],​[118],​[119] A more targeted prevention RCT would be valuable to examine these two possibilities; (iii) Even if SSRIs are found to be effective prophylactics for some people, about 15% to 20% of patients still developed IFN-MDD even when prescribed SSRIs, there fore antidepressants may not be universally effective. Other targets and approaches for prevention are needed; (iv) Most importantly, about half of the patients with a history of MDD remain resilient even during IFN-α treatment. Identifying the source of this resilience for potential replication in other patients would be beneficial.

SSRI Trial type (N) Baseline characteristics Diagnosis Comments
Paroxetine [80] RCT 18 vs 20 Melanoma patients; average HAM-D>5 DSM-IV Prevented INF-MDD. 2/18 vs 9/20
Paroxetine [55] RCT 14 vs 19 Average HAM-D<3 DSM-IV Did not prevent INF-MDD overall. 5/14 vs 6/19
Paroxetine [106] RCT 23 vs 29 Median MADRS = 3 DSM-IV or MADRS<15 Did not prevent INF-MDD overall 3/23 vs 6/29 Benefit for patients with baseline MADRS>3
Citalopram [104] Open label 10 vs 0 MDD history in remission HAM-D =17 1/10 had recurrence of INF-MDD
Paroxetine or Citalopram [120] Open label 8 vs 0 History of previous INF-MDD (Comparaison with prior IFN-α trial) HADS>8 0/8 had recurrence of IFN-MDD Small average increase in HADS scores
Citalopram [107] Open label 14 vs 11 Average MADRS>10; History of affective disorder DSM-IV 2/14 developed INF-MDD vs 7/11 in the comparison group
Various Open label 10 vs 21 History of any DSM-IV affective disorder DSM-IV 2/10 developed INF-MDD vs 10/21 in the comparison group
Table II. Studies examining prevention of IFN-MDD using antidepressants. Three randomized placebo-controlled trials (RCT), and four open-label studies examining the prevention of major depressive disorder (MDD), diagnosed using criteria from the Diagnostic and Statistical Manual of Mental Disorders-IV (DMS-IV), the Hamilton Depression rating scale (HAM-D), or the Montgomery-Asberg Depression Rating Scale (MADRS).

Modifiable risk factors for IFN-MDD

The goal for this work is preventative treatments that can be targeted towards specifically mitigating those mechanisms underlying vulnerability. Poor sleep quality prior to IFN-α treatment may be one such risk factor. [121],[122] Patients with scores greater than 10 on the Pittsburgh Sleep Quality Index, a validated self-report assessment of sleep quality, [123] were ten times more like to subsequently develop IFN-MDD than patients sleeping better than this. [122] This large effect size was evident even when controlling for other depression symptoms. It is also consistent with large epidemiological studies wherein insomnia predicted the subsequent development of MDD over follow-up intervals of 1 to 35 years. ​[124],​[125],​[126],​[127] As many treatments for sleep exist, this may be a potentially modifiable risk factor for preventing IFN-MDD. This has previously been suggested for MDD, [128] but may now be readily testable in patients about to be treated with IFN-α.

There is also evidence that increased age may be another risk factor for IFN-MDD, [129] although this is certainly not a consistent finding. [130],[131] Despite the fact that age itself is not modifiable, this could indicate the presence of agerelated modifiable risk factors. Related to this, elevated levels of inflammatory cytokines, such as interleukin-6 (IL-6), prior to IFN-a therapy have been associated with subsequent IFN-MDD. [132],[133] Additionally, a polymorphism in IL-6 that has been associated with increased IL-6 levels is predictive of IFN-MDD.[134] In the subset of people with increased IL-6 during IFN-α administration, the IL6 levels temporally predicted next month's depression symptoms. [133] This is consistent with cross-sectional studies in which elevated IL-6 levels are associated with MDD. [54],[132],​[135],​[136],​[137],​[138],​[139],​[140] Thus, increased IL-6 may be another plausibly modifiable target for preventive intervention in depressed individuals. Interestingly, IL-6 increases with age but can be modified by diet [141] and/or exercise. ​[142],​[143]

Potential premorbid risk factors for IFN-MDD that may be modifiable through psychosocial interventions could include social isolation [144] and neuroticism. [115],[145] However, when controlling for other premorbid risk factors, the effect size for these is fairly small. [146] Another risk factor may be a hyperactive stress response in the hypothalamic-pituitaryadrenal (HPA) axis. [147] Given the common association between abnormalities in the HPA axis and MDD, ​[148],​[149],​[150] this may also be a potentially useful predictive marker. Interestingly, HPA axis responsiveness can be therapeutically modifiable by antidepressants. [154] It is therefore plausible that patients with overactive HPA responses may be the subjects who benefit most from antidepressant prophylaxis. Consistent with this, stress-reactivity did correlate with depressive symptoms prior to IFN-α therapy [147] - and thus elevated stress-reactivity may be a potential predictor of the need for ”indicated“ SSRI prevention.

Genetic polymorphisms within the serotonergic system have also been associated with vulnerability to IFN-MDD. [134],[146],[155] Two studies have replicated the finding that a short allele in the serotonin transporter robustly increases risk for IFN-MDD. [134],[146] Vulnerability to tryptophan depletion has also been associated with polymorphisms in the 5-HT reuptake transporter. [59] Because IFN-MDD has been associated with lowered tryptophan levels during treatment, [57],[91],[93] - [156] this suggests that differences in serotonergic tone may leave some people vulnerable to IFN-MDD. It is also plausible that these are the same subjects who may benefit from SSRI prophylaxis, a possibility that requires testing.

Interestingly, gender has not been a consistent predictor of IFN-MDD, [37],[157],[158] which suggests that IFN-MDD maybe partially distinct from some forms of MDD that are unique to females. Also, as long as patients remain abstinent, a past history- of drug and alcohol abuse is not predictive of increased risk. [15],[37],[131] This suggests that risks for drug and alcohol abuse are distinct from risk for IFN-MDD. One critical implication is that a past history of drug use, in remission, is not a contraindication to prescribing IFN-α. Nonetheless, several leads are now suggested by these various predictive risk factors, several of which may be amenable to modification. The IFN-MDD paradigm has now been used in several studies to examine whether SSRIs can prevent depression. It may now be useful to determine whether other preventive treatments are effective.

Other populations at selective risk for MDD

In summary, encouraging results indicate that: (i) specific patients may be at elevated risk for IFN-MDD; (ii) this vulnerability may be identifiable prior to IFN-α treatment; (iii) some sources of this vulnerability (such as poor sleep) may be modifiable; and (iv) therefore personalized prevention is testable and could become a reality. Because of the high incidence of IFN-MDD in the first few months of treatment, and the ability to recruit nondepressed patients prior to IFN-α treatment, examining these possibilities appears to be practical and feasible in this population. Several studies with prophylactic SSRIs have already occurred. Furthermore, because of the homologies between IFN-MDD and MDD in general, any lessons learned from IFN-MDD may be translatable to other types of MDD. As examples, MDD occurs at higher rates in populations with multiple chronic illnesses, [159] during bereavement, [160] in caregivers of demented patients, [161] in stroke survivors, ​[162],​[163],​[164] in postpartum mothers, [1 ],[10],[165] and there is preliminary evidence that MDD incidence could potentially be reduced in these settings. [161],[167] Similar to IFN-MDD, most people in these settings are resilient to developing MDD, with only a subset who are vulnerable. [168]

Conclusion

It remains an intriguing possibility that modifiable risk factors identified for IFN-MDD may also be modifiable risk factors in these other settings. Thus, targeting the appropriate prevention to the appropriate patient may be possible, and this may soon lead to the personalized prevention of MDD.

REFERENCES
1. Kendler KS, Prescott CA. A population-based twin study of lifetime major depression in men and women. Arch Gen Psychiatry 1999;56:39-44 [ Pub Med ]
2. Coyne JC, Fechner-Bates S, Schwenk TL. Prevalence, nature, and comorbidity of depressive disorders in primary care. Gen Hosp Psychiatry 1994;16:267-276 [ Pub Med ]
3. Stoudemire A, Frank R, Hedemark N, Kamlet M, Blazer DG. The economic burden of depression. Gen Hosp Psychiatry 1986;8:387-394 [ Pub Med ]
4. Patten SB. Long-term medical conditions and major depression in a Canadian population study at waves 1 and 2. J Affect Dis 2001;63:35-41 [ Pub Med ]
5. Blazer DG. Mood disorders: Epidemiology. In: Sadock BJ, Sadock VA, eds. Comprehensive Textbook of Psychiatry. 7th ed. Philadelphia, PA: Lippincott Williams amp; Williams. 2000:1298-1307
6. Eaton WW, Kramer M, Anthony JC, Dryman A, Shapiro S, Locke BZ. The incidence of specific DIS/DSM-III mental disorders: data from the NIMH Epidemiologic Catchment Area Program. Acta Psych Scand 1989;79:163 [ Pub Med ]
7. Hagnell O, Lanke J, Rorsman B, Ojesjo L. Are we entering an age of melancholy? Depressive illnesses in a prospective study epidemiological study over 25 years: the Lundby Study. Psychol Med 1982;12:279-289 [ Pub Med ]
8. Loftis JM, Hauser P. The phenomenology and treatment of interferoninduced depression. J Affect Disord 2004;82:175-190 [ Pub Med ]
9. Asnis GM, De La Garza R. 2nd Interferon-induced depression in chronic hepatitis C: a review of its prevalence, risk factors, biology, and treatment approaches. J Clin Gastroenterol 2006;40:322-335 [ Pub Med ]
10. Schaefer M, Engelbrecht MA, Gut O, et al. . Interferon alpha (IFNalpha) and psychiatric syndromes: a review. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:731-746 [ Pub Med ]
11. Trask PC, Esper P, Riba M, Redman B. Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions. J Clin Oncol 2000;18:2316-26 [ Pub Med ]
12. Raison CL, Demetrashvili M, Capuron L, Miller AH. Neuropsychiatrie adverse effects of interferon-alpha: recognition and management. CNS Drugs 2005;19:105-123 [ Pub Med ]
13. Reichenberg A, Gorman JM, Dieterich DT. Interferon-induced depression and cognitive impairment in hepatitis C virus patients: a 72 week prospective study. AIDS 2005;19:S174-S178 [ Pub Med ]
14. Dieperink E, Ho SB, Thuras P, Willenbring ML. A prospective study of neuropsychiatrie symptoms associated with interferon-a-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomat 2003;44:104-112 [ Pub Med ]
15. Hauser P, Khosla J, Aurora H, et al. . A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry 2002;7:942-947 [ Pub Med ]
16. Castera L, Constant A, Henry C, et al. . Impact on adherence and sustained viological response of psychiatric side effects during peginterferon and ribavirin therapy for chronic hepatitis C. Alimentary Pharmacol Therapeut 2006;24:1223-1230 [ Pub Med ]
17. Schaefer M, Schmidt F, Horn M, Schmid-Wendtner M-H, Volkenandt M. Depression during treatment with interferon alpha. Psychosomat 2004:45-176
18. Raison CL, Demetrashvili M, Capuron L, Miller AH. Neuropsychiatrie adverse effects of interferon-a: recognition and management. CNS Drugs 2005;19:105-123 [ Pub Med ]
19. Cotler SJ, Wartelle CF, Larson AM, Gretch DR, Jensen DM, Carithers RLJ. Pretreatment symptoms and dosing regimen predict side-effects of interferon therapy for hepatitis C. J Viral Hepatitis 2000;7:211-217 [ Pub Med ]
20. Dieperink E, Willenbring M Ho SB. Neuropsychiatrie symptoms associated with hepatitis C and interferon alpha: a review. Am J Psychiatry 2000;157:867-876 [ Pub Med ]
21. Malaguarnera M, Di Fazio I, Restuccia S, Pistone G, Ferlito L, Rampello L. Interferon alpha-induced depression in chronic hepatitis C patients: Comparison between different types of interferon alpha. Neuropsychobiol 1998;37:93-97 [ Pub Med ]
22. Capuron L, Hauser P, Hinze-Selch D, Miller AH, Neveu PJ. Treatment of cytokine-induced depression. Brain Behav Immunology 2002;16:575-580 [ Pub Med ]
23. Donnelly S. Patient management strategies for interferon alfa-2b as adjuvant therapy of high-risk melanoma. Oncologic Nursing Forum 1998;25:921-927 [ Pub Med ]
24. Trask PC, Esper P, Riba M, Redman B. Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions. J Clin Oncol 2000;18:2316-2326 [ Pub Med ]
25. Pavol MA, Meyers CA, Rexer JL, Valentine AD, Mattis PJ, Talpaz M. Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia. Neurol 1995;45:947-950 [ Pub Med ]
26. Malaguarnera M, Laurino A, Di Fazio I, et al. . Neuropsychiatrie effects and type of IFN-a in chronic hepatitis C. J Interferon Cytokine Res 2001;21:273-278 [ Pub Med ]
27. Renault PF, Hoofnagle JH, Park Y, et al. . Psychiatric complications of long-term interferon alfa therapy. Arch IntMed 1987;147:1577-1580 [ Pub Med ]
28. Capuron L, Gumnick JF, Musselman DL, et al. . Neurobehavioral effects of interferon-a in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacol 2002;26:643-652 [ Pub Med ]
29. Hosoda S, Takimura H, Shibayama M, Kanamura H, Ikeda K, Kumada H. Psychiatric symptoms related to interferon therapy for chronic hepatitis C: clinical features and prognosis. Psychiatry Clin Neurosci 2000;54:565-572 [ Pub Med ]
30. Bonaccorso S, Marino V, Biondi M, Grimaldi F, Ippoliti F, Maes M. Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus. J Affect Dis 2002;72:237-241 [ Pub Med ]
31. Lin R, Roach E, Zimmerman M, Strasser S, Farrell GC Group) AHCS. Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. J Hepatol 1995;23:487-496 [ Pub Med ]
32. Spath-Schwalbe E, Lange T, Perras B, Fehm HL, Born J. Interferon-alpha acutely impairs sleep in healthy humans. Cytokine 2000;12:518-521 [ Pub Med ]
33. Poutiainen E, Hokkanen L, Niemi M, Farkkila M. Reversible cognitive decline during high-dose [alpha]-interferon treatment. Pharmacol Biochem Behav 1994;47:901-905 [ Pub Med ]
34. Merimsky O, Reider-Groswasser I, Inbar M, Chaitchik S. Interferonrelated mental deterioration and behavioral changes in patients with renal cell carcinoma. Eur J Cancer 1990;26:596-600 [ Pub Med ]
35. McHutchinson JG, Manns M, Patel K, et al. . Adherence to combination therapy enhances sustained response in genotype-1-infected patents with chronic hepatitis C. Gastroenterol 2002;122:1061-1069 [ Pub Med ]
36. Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatol 1997;26:112S-121S [ Pub Med ]
37. Fontana RJ, Schwartz SM, Gebremariam A, Lok ASF, Moyer CA. Emotional distress during interferon-a-2B and ribavirin treatment of chronic hepatitis C. Psychosomat 2002;34:378-385 [ Pub Med ]
38. Janssen H, Brouwer J, van der Mast R, Schalm S. Suicide associated with alfa-interferon therapy for chronic viral hepatitis. J Hepatol 1994;21:241-243 [ Pub Med ]
39. McHutchison JG, Gordon SC, Schiff ER, et al. . Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-1492 [ Pub Med ]
40. Enns MW, Cox BJ. Personality dimensions and depression: review and commentary. Can J Psychiatry - Revue Canadienne de Psychiatrie 1997;42:274-284 [ Pub Med ]
41. Boyce P, Mason C. An overview of depression-prone personality traits and the role of interpersonal sensitivity. Austr New Zealand J Psychiatry 1996;30:90-103 [ Pub Med ]
42. Joiner TE. Depression in its interpersonal context. In: Gotlieb IH, Hammen CL, eds. Handbook of Depression. New York, NY: Guilford. 2002:295-313
43. Fabrega HJ. Disease and Social Behavior: an Interdisciplinary Perspective. Cambridge, MA: MIT Press. 1974
44. Mullen L.S, Blanco C, Vaughan SC, Vaughan R, Roose SP. Defense mechanisms and personality in depression. Depress Anx 1999;10:168-174 [ Pub Med ]
45. Gilbert P. Evolutionary approaches to psychopathology: the role of natural defences. Aust N Z J Psychiatry 2001;35:17-27 [ Pub Med ]
46. Parker G, Lipscombe P. The relevance of early parental experiences to adult dependency, hypochondriasis and utilization of primary physicians. Br J Med Psychol 1980;53:355-363 [ Pub Med ]
47. Granek M. Hypochondriasis, acting out and counter-acting out. Br J Med Psychol 1989;62:257-264 [ Pub Med ]
48. Hofmann AD. The impact of illness in adolescence and coping behavior. Acta Paediatrica Scand (Supplement) 1975;256:29-33 [ Pub Med ]
49. Scheurich N. Hysteria and the medical narrative. Persp Biol Med 2000;43:461-476 [ Pub Med ]
50. Kihlstrom JF, Cantor Kihlstrom L. Somatization as illness behavior. Adv Mind-Body Med 2001;17:240-243 [ Pub Med ]
51. Maes M. Psychological stress, cytokines, and the inflammatory response system. Curr Opin Psychiatry 1999;12:695-700 [ Pub Med ]
52. Schwarz MJ, Chiang S, Muller N, Ackenheil M. T-Helper-1 and T-helper2 responses in psychiatric disorders. Br Behav Immunol 2001;15:340-370 [ Pub Med ]
53. Vollmer-Conna U. Acute sickness behavior: an immune system-to-brain communication? Psychol Med 2001;31:761-767 [ Pub Med ]
54. Miller GE, Rohleder N, Stetler C, et al. . Clinical depression and regulation of the inflammatory response during acute stress. Psychosomat Med 2005;67:679-687 [ Pub Med ]
55. Pace TW, Mletzko TC, Alagbe O, et al. . Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress. Am J Psychiatry 2006;163:1630-1633 [ Pub Med ]
56. Morikawa O, Sakai N, Obara H, Saito N. Effects of interferon-alpha, interferon-gamma and cAMP on the transcriptional regulation of the serotonin transporter. Eur J Pharmacol 1998;349:317-324 [ Pub Med ]
57. Bonaccorso S, Marino V, Puzella A, et al. . Increased depressive ratings in patients with hepatitis C receiving interferon-[alpha]-based immunotherapy are related to interferon-[alpha]-induced changes in the serotonergic system. J Clin Psychopharmacol 2002;22:86-90 [ Pub Med ]
58. Rosel P, Arranz B, Vallejo J, et al. . Altered [3H]imipramine and 5-HT2 but not [3H]paroxetine binding sites in platelets from depressed patients. J Affect Dis 1999;52:225-233 [ Pub Med ]
59. Neumeister A, Konstantinidis A, Stastny J, et al. . Association between serotonin transporter gene promoter polymorphism (5HTTLPR) and behavioral responses to tryptophan depletion in healthy women with and without family history of depression. Arch Gen Psychiatry 2002;59:613-620 [ Pub Med ]
60. Shuto H, Kataoka Y, Horikawa T, Fujihara N, Oishi R. Repeated interferon-a administration inhibits dopaminergic neural activity in the mouse brain. Br Res 1997;747:348-351 [ Pub Med ]
61. Song C, Merali Z, Anisman H. Variations of nucleus accumbens dopamine and serotonin following systemic interfleukin-1, interleukin-2, or interleukin-6 treatment. Neurosci 1999;88:823-836 [ Pub Med ]
62. Hanisch U-K, Quirion R. Interleukin-2 as a neuroregulatory cytokine. Br Re Rev 1996;21:246-284 [ Pub Med ]
63. Song C, Lin A, Bonaccorso S, et al. . The inflammatory response system and the availability of plasma tryptophan in patients with primary sleep disorders and major depression. J Affect Dis 1998;49:211-219 [ Pub Med ]
64. Katafuchi T, Kondo T, Yasaka T, Kubo K, Take S, Yoshimura M. Prolonged effects of polyriboinosinicpolyribocytidylic acid on spontaneous running wheel activity and brain interferon-alpha mRNA in rats: a model for immunologically induced fatigue. Neurosci 2003;120:837-845 [ Pub Med ]
65. Licinio J, Wong M-L. Pathways and mechanisms for cytokine signaling of the central nervous system. J Clin Invest 1997;100:2941-2947 [ Pub Med ]
66. Hansen MK, Taishi P, Chen Z, Krueger JM. Vagotomy blocks the induction of interleukin-1b (IL-1b) mRNA in the brain of rats in response to systemic IL-1b. J Neurosci 1998;18:2247-2253 [ Pub Med ]
67. Yirmiya R, Pollak Y, Baak O, et al. . Effects of antidepressant drugs on the behavioral and physiological responses to lipopolysaccharide (LPS) in rodents. Neuropsychopharmacol 2001;24:531-544 [ Pub Med ]
68. Anisman H, Kokkinidis L, Merali Z. Further evidence for the depressive effects of cytokines: Anhedonia and neurochemical changes. Br Behav Immunol 2002;16:544-556 [ Pub Med ]
69. Larson SJ. Behavioral and motivational effects of immune-system activation. J Gene Psychol 2002;129:401-414 [ Pub Med ]
70. Larson SJ, Dunn AJ. Behavioral effects of cytokines. Br Behav Immun 2001;15:371-387 [ Pub Med ]
71. Dantzer R, Aubert A, Bluthe R-M, et al. . Mechanisms of the behavioral effects of cytokines. Adv Exp Med Biol 1999;461:83-106 [ Pub Med ]
72. Dantzer R, Kelley KW. Twenty years of research on cytokine-induced sickness behavior. Br Behav Immun 2007;21:153-160 [ Pub Med ]
73. Maier SF, Nguyen KT, Deak T, Milligan ED, Watkins LR. Stress, learned helplessness, and brain interleukin-1b. Adv Exp Med Biol 1999;461:235-250 [ Pub Med ]
74. Makino M, Kitano Y, Komiyama C, Hirohashi M, Takasuna K. Involvement of central opioid systems in human interferon-a induced immobility in the mouse forced swimming test. Br J Pharmacol 2000;130:1269-1274 [ Pub Med ]
75. Makino M, Kitano Y, Komiyama C, Takasuna K. Human interferon-a increases immobility in the forced swimming test in rats. Psychopharmacol 2000;148:106-110 [ Pub Med ]
76. Schramm TM, Lawford BR, Macdonald GA, Cooksley WG. Sertraline treatment of interferon-alfa-induced depressive disorder. Med J Aust 2000;173:359-361 [ Pub Med ]
77. Gleason OC, Yates WR. Five cases of interferon-a-induced depression treated with antidepressant therapy. Psychosomat 1999;40:510-512 [ Pub Med ]
78. Gleason OC, Yates WR, Isbell MD, Philipsen MA. An open-label trial of citalopram for major depression in patients with hepatitis C. J Clin Psychiatry 2002;63:194-198 [ Pub Med ]
79. Kraus MR, Schafer A, Schottker K, et al. . Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomized, doubleblind, placebo-controlled study. Gut 2008;57:531-536 [ Pub Med ]
80. Musselman DL, Lawson DH, Gumnick JF, et al. . Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001;344:961-966 [ Pub Med ]
81. Goldman LS. Successful treatment of interferon-a-induced mood disorders with nortriptyline. Psychosomat 1994;35:412-413 [ Pub Med ]
82. Levenson JL, Fallon HJ. Fluoxetine treatment of depression caused by interferon-a. Am J Gastroenterol 1993;88:760-761 [ Pub Med ]
83. Hauser P, Soler R, Reed S, et al. . Prophylactic treatment of depression induced by interferon-a. Psychosomat 2000;41:439-442 [ Pub Med ]
84. Farah A. Interferon-induced depression treated with citalopram. J Clin Psychiatry 2002;63:166-167 [ Pub Med ]
85. Morasco BJ, Rifai MA, Loftis JM, Indest DW, Moles JK, Hauser P. A randomized trial of paroxetine to prevent interferon-a-induced depression in patients with hepatitis C. J Affect Dis 2007;103:83-90 [ Pub Med ]
86. Horikawa N, Yamazaki T, Izumi N, Uchihara M. Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospective study. Gen Hosp Psychiatry 2003;25:34-38 [ Pub Med ]
87. Hauser P, Khosla J, Aurora H, et al. . A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry 2002;7:942-947 [ Pub Med ]
88. Juengling FD, Ebert D, Gut O, et al. . Prefrontal cortical hypometabolism during low-dose inteferon alpha treatment. Psychopharmacol 2001;152:383-389 [ Pub Med ]
89. Capuron L, Pagnoni G, Demetrashvili M, et al. . Anterior cingulate activation and error processing during interferon-alpha treatment. Biol Psychiatry 2005;58:190-196 [ Pub Med ]
90. Abe S, Hori T, Suzuki T, Baba A, Shiraishi H, Yamamoto T. Effects of chronic administration of interferon alpha A/D on serotonergic receptors in rat brain. Neurochemic Res 1999;24:359-363 [ Pub Med ]
91. Capuron L, Neurauter G, Musselman DL, et al. . Interferon-alpha-induced changes in tryptophan metabolism, relationship to depression and paroxetine treatment. Biol Psychiatry 2003;54:906-914 [ Pub Med ]
92. Dunn AL, Crnic LS. Repeated injections of interferon-alpha A/D in Balb/c mice: behavioral effects. Brain Behav Immun 1993;7:104-111 [ Pub Med ]
93. Wichers MC, Maes M. The role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon-alpha-induced depression. J Psychiatry Neurosci 2004;29:11-17 [ Pub Med ]
94. Chou R, Clark EC, Helfand M. Screening for Hepatitis C virus infection: a review of the evidence for the U.S. Preventive Services Task Force. Ann Int Med 2004;140:465-479 [ Pub Med ]
95. Baron S, Tyring SK, Fleischmann WR. The interferons: mechanisms of action and clinical applications. JAMA 1991;266:1375-1383 [ Pub Med ]
96. Borden EC, Parkinson D. A perspective on the clinical effectiveness and tolerance of interferon-(alpha). Sem Oncol 1998;25:3-8 [ Pub Med ]
97. Memon Ml, Memon MA. Hepatitis C: an epidemiological review. J Viral Hepatitis 2002;9:84-100 [ Pub Med ]
98. Williams I. Epidemiology of hepatitis C in the United States. Am J Med 1999;107:2S-9S [ Pub Med ]
99. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention, MMWR Recomm Rep 1998;47:1-39 [ Pub Med ]
100. Zdilar D, Franco-Bronson K, Buchler N, Locala JA, Younossi ZM. Hepatitis C, interferon alfa, and depression. Hepatol 2000;31:1207-1211 [ Pub Med ]
101. Castera L, Constant A, Henry C, Couzigou P. Psychiatric disorders during treatment of chronic hepatitis C. Gastroenterol Clin Biol 2005;29:123-133 [ Pub Med ]
102. Dan AA, Martin LMC, Ong JP, et al. . Depression, anemia and healthrelated qulity of life in chronic hepatitis C.J Hepatol 2006;44:491-498 [ Pub Med ]
103. Younossi Z, Kallman J, Kincaid J. The effects of HCV infection and management on health-related quality of life. Hepatol 2007;45:806-816 [ Pub Med ]
104. Gleason OC, Fucci JC, Yates WR, Philipsen MA. Preventing relapse of major depression during interferon-a therapy for hepatitis C - a pilot study. Dig Dis Sci 2007;52:2557-2563 [ Pub Med ]
105. Kraus MR, Schafer A, Scheurlen M. Paroxetine for the prevention of depression induced by interferon alfa. N Engl J Med 2001;345:375-376 [ Pub Med ]
106. Raison CL, Woolwine BJ, Demetrashvili ZM, et al. . Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C. Alimentary Pharmacol Therapeut 2007;25:1163-1174 [ Pub Med ]
107. Schaefer M, Schwaiger M, Garkish AS, et al. . Prevention of interferonalpha associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol 2005;42:793-798 [ Pub Med ]
108. Cuijpers P, Smit F, Straten A. Psychological treatment of subthreshold depression: a systematic review. Acta Psychiatrica Scand 2007;115:434-441 [ Pub Med ]
109. Rovner BW, Casten RJ. Preventing late-life depression in age-related macular degeneration. Am J Geriatr Psychiatry 2008;16:454-459 [ Pub Med ]
110. Munoz RF, Le HL, Ghosh-lppen C, Diaz MA, Urizar GG, Soto J. Prevention of postpartum depression in low-income women: Development of the mams y bebs/mothers and babies course. Cog Behav Practice 2007;14:70-83 [ Pub Med ]
111. Schoevers RA, Smit F, Deeg DJH, et al. . Prevention of late-life depression in primary care: do we know where to begin? Am J Psychiatry 2006;163:1611-1621 [ Pub Med ]
112. Capuron L, Ravaud A. Prediction of the depressive effects of interferon alfa therapy by the patients initial affective state. N Engl J Med 1999:340:1370 [ Pub Med ]
113. Raison CL, Borisov AS, Broadwell SD, et al. . Depression during pegylated interferon-alpha plus ribarin therapy: prevalence and prediction. J Clin Psychiatry 2005;66:41-48 [ Pub Med ]
114. Lotrich FE, Ferrell RE, Rabinovitz M, Pollock BG. Risk for depression during interferon-alpha treatment is affected by the serotonin transporter polymorphism. Biol Psychiatry 2009;65:344-348 [ Pub Med ]
115. Lotrich FE, Rabinovitz F, Gironda P, Pollock BG. Depression following pegylated interferon-alpha: characteristics and vulnerability. J Psychosomat. Res. 2007;63:131-135 [ Pub Med ]
116. Frank E, Kupfer DJ, Perel JM, Cornes C, Jarret DB, Mallinger AG. Threeyear outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1990;47:1093-1099 [ Pub Med ]
117. Geddes JR, Carney SM, Davies CH, Furukawa TA, Kupfer DJ. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 2003;361:653-661 [ Pub Med ]
118. Klein DN, Santiago NJ, Vivian D, Arnow BA, Blalock JA, Dunner DL. Cognitive-behavioral analysis system of psychotherapy as a maintenance treatment for chronic depression. J Consul Clin Psychol 2004;72:681-688 [ Pub Med ]
119. Fava GA, Ruini C, Rafanelli C, Finos L, Conti S, Grandi S. Six-year outcome of cognitive behavior therapy for prevention of recurrent depression. Arch Gen Psychiatry 2004;161:1872-1876 [ Pub Med ]
120. Kraus MR, Shafer A, Al-Taie O, Scheurlen M. Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression. J Viral Hepatitis 2006;12:96-100 [ Pub Med ]
121. Capuron L, Ravaud A, Miller AH, Dantzer R. Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy. Br Behav Immunol 2004;18:205-213 [ Pub Med ]
122. Franzen PL, Buysse DJ, Rabinovitz M, Pollock BG, Lotrich FE. Poor sleep quality predicts onset of either major depression or subsyndromal depression with irritability during interferon-alpha treatment. Psychiatric Research 2009 In press.
123. Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatric Research 1989;28:193-213 [ Pub Med ]
124. Ford DE, Kamerow DB. Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention? JAMA 1989;262:1479-1484 [ Pub Med ]
125. Breslau N, Roth T, Rosenthal L, Andreski P. Sleep disturbance and psychiatric disorders: a longitudinal epidemiological study of young adults. Biol Psychiatry 1996;39:411-418 [ Pub Med ]
126. Riemann D, Voderholzer U. Primary insomnia: a risk factor to develop depression? J Affect Disord 2003;76:255-259 [ Pub Med ]
127. Chang PP, Ford DE, Mead LA, Cooper-Patrick L, Klag MJ. Insomnia in young men and subsequent depression. The Johns Hopkins Precursors Study. Am J Epidemiol 1997;146:105-114 [ Pub Med ]
128. Ford DE, Kamerow DB. Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention? JAMA 1989;262:1479-1484 [ Pub Med ]
129. Horikawa N, Yamazaki T, Izumi N, Uchihara M. Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospective study. Gen Hosp Psychiatry 2003;25:34-38 [ Pub Med ]
130. Miyaoka H, Otsubo T, Kamijima K, Ishii M, Onuki M, Mitamura K. Depression from interferon therapy in patients with hepatitis C. Am J Psychiatry 1999;156:1120 [ Pub Med ]
131. Kraus MR, Schafer A, Falter H, Csef H, Scheurlen M. Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. J Clin Psychiatry 2003;64:708-714 [ Pub Med ]
132. Wichers MC, Kenis G, Leue C, Koek G, Robaeys G, Maes M. Baseline immune activation as a risk factor for the onset of depression during interferon-alpha treatment. Biol Psychiatry 2006;60:77-79 [ Pub Med ]
133. Prather AA, Rabinovitz M, Pollock BG, Lotrich FE. Cytokine-induced depression during IFN-a treatment: the role of IL-6 and sleep quality. Brain Behav Immun 2009;23:1109-1116 [ Pub Med ]
134. Bull SJ, Huezo-Diaz P, Binder EB, et al. . Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-a and ribavirin treatment. Mol Psychiatry 2008;14:110 [ Pub Med ]
135. Pike JL, Irwin MR. Dissociation of inflammatory markers and natural killer cell activity in major depressive disorder. Br Behav Immun 2006;20:169-174 [ Pub Med ]
136. Maes M, Meltzer HY, Bosnians E, et al. . Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J Affect Disord 1995;34:301-309 [ Pub Med ]
137. Frommberger UH, Bauer J, Haselbauer P, Fraulin A, Riemann D, Berger M. lnterleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Eur Arch Psychiatry Clin Neurosci 1997;247:228-233 [ Pub Med ]
138. Sluzewska A, Rybakowski J, Bosmans E, et al. . Indicators of immune activation in major depression. Psychiatry Res 1996;64:161-167 [ Pub Med ]
139. Musselman DL, Miller AH, Porter MR, et al. . Higher than normal plasma interleukin-6 concetrations in cancer patients with depression: preliminary findings. Am J Psychiatry 2001;158:1252-1257 [ Pub Med ]
140. Dimopoulos N, Piperi C, Psarra V, Lea RW, Kalofoutis A. Increased plasma levels of 8-iso-PGF2alpha and IL-6 in an elderly population with depression. Psychiatry Res 2008;161:59-66 [ Pub Med ]
141. Mariani E, Neri S, Cattini L, et al. . Effect of zinc supplementation on plasma IL-6 and MCP-1 production and NK cell function in healthy elderly: interactive influence of +647 MT1a and -174 IL-6 polymorphic alleles. Exp Gerontol 2008;43:462-471 [ Pub Med ]
142. Nicklas BJ, Hsu F-C, Brinkley TJ, et al. . Exercice training and plasma C-reactive protein and interleukin-6 in elderly people. J Am Geriatr Soc 2008;56:2045-2052 [ Pub Med ]
143. Lambert CP, Wright NR, Finck BN, Villareal DT. Exercise but not dietinduced weight loss decreases skeletal muscle inflammatory gene expression in frail obese elderly persons. J App Physiol 2008;105:473-478 [ Pub Med ]
144. McDonald EM, Mann AH, Thomas HC. Interferons as mediators of psychiatric morbidity: an investigation in a trial of recombinant a-interferon in hepatitis-B carriers. Lancet 1987;11:1175-1178 [ Pub Med ]
145. Otsubo T, Miyaoka H, Kamijima K, Onuki M, Ishii M, Mitamura K. Depression during interferon therapy in chronic hepatitis C patients - a prospective study. Seishin Shinkeigaku Zasshi (Jpn) 1997;99:101-127 [ Pub Med ]
146. Lotrich FE, Ferrell RE, Rabinovitz M, Pollock BG. Risk for depression during interferon-alpha treatment is affected by the serotonin transporter polymorphism. Biol Psychiatry 2009;65:344-348 [ Pub Med ]
147. Capuron L, Raison CL, Musselman DL, Lawson DH, Nemeroff CB, Miller AH. Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy. Am J Psychiatry 2003;160:1342-1345 [ Pub Med ]
148. Pace TWW, Hu F, Miller AH. Cytokine-effects on glucocorticoid receptor function: relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression. Br Behav Immun 2007;21:9-19 [ Pub Med ]
149. Pariante CM, Miller AH. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry 2001;49:391-404 [ Pub Med ]
150. Antonijevic I. HPA axis and sleep: identifying subtypes of major depression. Stress 2008;11:15-27 [ Pub Med ]
151. Heydendael W, Jacobson L. Differential effects of imipramine and phenelzine on corticosteroid receptor gene expression in mouse brain: potential relevance to antidepressant response. Brain Res 2008;1238:93-107 [ Pub Med ]
152. Carvalho LA, Pariante CM. In vitro modulation of the glucocorticoid receptor by antidepressants. Stress 2008;11:411-424 [ Pub Med ]
153. Simon NG, Guillon C, Fabio K, et al. . Vasopressin antagonists as anxiolytics and antidepressants: recent developments. Recent Patents on CNS Drug Discovery 2008;3:77-93 [ Pub Med ]
154. ihara M, Ida I, Yuuki N, et al. . HPA axis dysfunction in unmedicated major depressive disorder and its normalization by pharmacotherapy correlates with alteration of neural activity in prefrontal cortex and limbic/paralimbic regions. Psychiatry Res 2007;155:245-256 [ Pub Med ]
155. Kraus MR, Al-Taie O, Schefer A, Pfersdorff M, Lesch KP, Scheurlen M. Serotonin-1 A receptor gene (HTR1 A) variation predicts interferon-induced depression chronic hepatitis C. Gastroenterol 2007;132:1279-1286 [ Pub Med ]
156. Capuron L, Ravaud A, Neveu PJ, Miller AH, Maes M, Dantzer R. Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry 2002;7:468-473 [ Pub Med ]
157. Gohier B, Goeb JL, Rannou-Dubas K, Fouchard I, Cales P, Garre JB. Hepatitis C, alpha interferon, anxiety and depression disorders: a prospective study of 71 patients. World J Biol Psychiatry 2003;4:115-118 [ Pub Med ]
158. Koskinas J, Merkouraki P, Manesis E, Hadziyannis S. Assessment of depression in patients with chronic hepatitis: effect of interferon treatment. Dig Dis Sci 2002;20:284-288 [ Pub Med ]
159. Smits F, Smits N, Schoevers R, Deeg D, Beekman A, Cuijpers P. An epidemiological approach to depression prevention in old age. Am J Geriatr Psychiatry 2008;16:444-453 [ Pub Med ]
160. Cole MG. Evidence-based review of risk factors for geriatric depression and brief preventative interventions. Psychiatr Clin N Am 2005;28:785-803 [ Pub Med ]
161. Brodaty H, Green AA, Koschera A. Meta-analysis of psychosocial interventions for caregivers of people with dementia. J Am Geriatr Soc 2003;51:657-664 [ Pub Med ]
162. Forster A, Young J. Specialist nurse support for patients with stroke in the community: a randomized controlled trial. BMJ 1996;312:1642-1646 [ Pub Med ]
163. Narushima K, Kosier TJ, Robinson RG. Preventing poststroke depression: a 12-week double blind randomized treatment trial and 21-month follow-up. J Nerv Ment Dis 2002;190:296-303 [ Pub Med ]
164. Rasmussen BB, Lunde M, Loldrup PD, et al. . A double-blind placebo-controlled study of sertraline in the prevention of depression in stroke patients. Psychosornatics 2003;44:216-221 [ Pub Med ]
165. Austin MP. Targeted group antenatal prevention of postnatal depression: a review. Acta Psychiatrica Scand 2003;107:2444-2250 [ Pub Med ]
166. Dennis CLE. Preventing postpartum depression Part II: a critical view of nonbiological interventions. Can J Psychiatry 2004;49:526-538 [ Pub Med ]
167. Cole MG. Brief interventions to prevent depression in older subjects: a systematic review ofe feasibility and effectiveness. Am J Geriatr Psychiatry 2008;16:435-443 [ Pub Med ]
168. Barrera AZ, Torres LD, Munoz RF. Prevention of depression: the state of the science at the beginning of the 21st century. Int Rev Psychiatry 2008;19:655-670 [ Pub Med ]